Skip to content

RSV Antibiotic Drivers And Resource-use

Evaluation of Clinical, Laboratory, and Radiologic Parameters Affecting Antibiotic Use and Associated Cost in RSV-Positive Children With Acute Lower Respiratory Tract Infections

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06977971
Acronym
RADAR
Enrollment
209
Registered
2025-05-18
Start date
2017-04-01
Completion date
2023-10-01
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Stewardship in Community Hospitals, Respiratory Syncytial Virus Infections

Keywords

Respiratory Syncytial Virus Infections, Anti-Bacterial Agents, Health Care Costs, Polymerase Chain Reaction, C-Reactive Protein

Brief summary

This study retrospectively evaluated the clinical, laboratory, and radiologic factors that influence the decision to prescribe antibiotics in children under 2 years of age hospitalized with RSV-positive acute lower respiratory tract infections. The study also examined the economic impact of antibiotic use in these patients. The goal is to improve clinical decision-making and reduce unnecessary antibiotic exposure in children with viral infections.

Detailed description

This retrospective, single-center study aimed to assess the clinical decision-making process regarding antibiotic prescription in children aged 1 to 24 months hospitalized with RSV-positive acute lower respiratory tract infections (ALRTI). The study was conducted at Dr. Behçet Uz Children's Hospital and covered four consecutive RSV seasons (April 2017 - April 2021). RSV infection was confirmed via multiplex PCR. Clinical and laboratory variables potentially influencing antibiotic use included fever, respiratory distress, CRP levels, leukocyte count, and radiologic findings such as infiltrates on chest X-ray. The study also examined whether antibiotic selection (agent, timing, and duration) was associated with specific clinical profiles or severity indicators. Hospitalization cost data were analyzed to estimate the economic burden of antibiotic use in RSV-positive patients. The study contributes to improved antimicrobial stewardship by identifying patterns of potentially unnecessary antibiotic prescriptions in viral respiratory infections. Ethical approval was obtained from the local ethics committee (Approval No: 2021-634), and the study adhered to the principles of the Declaration of Helsinki.

Interventions

None listed

Sponsors

Dr. Behcet Uz Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 24 Months
Healthy volunteers
No

Inclusion criteria

* Age between 1 and 24 months at the time of hospitalization * Laboratory-confirmed RSV positivity via multiplex PCR * Hospitalized for acute lower respiratory tract infection * Complete hospitalization and clinical data available

Exclusion criteria

* Detection of additional respiratory pathogens on multiplex PCR * Discharge against medical advice before treatment was completed * Missing or incomplete key clinical, laboratory, or radiologic data * ICU admission without full follow-up data

Design outcomes

Primary

MeasureTime frameDescription
Association between clinical/laboratory/radiologic parameters and antibiotic prescriptionDuring hospitalization (April 2017 - April 2021)This outcome assesses the relationship between objective findings (e.g., CRP levels, abnormal chest X-ray, fever) and the decision to initiate antibiotic therapy in RSV-positive children aged 1-24 months hospitalized with acute lower respiratory tract infections.

Secondary

MeasureTime frameDescription
Total antibiotic-related hospitalization cost per patientDuring hospitalization (April 2017 - April 2021)This outcome evaluates the economic impact of antibiotic use by calculating the direct hospitalization costs associated with antibiotic treatment in RSV-positive pediatric patients.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026